- Market Capitalization, $K 125,059,768
- Shares Outstanding, K 2,443,528
- Annual Sales, $ 17,099 M
- Annual Income, $ 5,906 M
- 60-Month Beta 0.58
- Price/Sales 7.07
- Price/Cash Flow 18.64
- Price/Book 17.40
|Period||Period Low||Period High||Performance|
| || |
+2.36 (+4.86%)since 05/24/19
| || |
-0.99 (-1.91%)since 03/26/19
| || |
+4.87 (+10.57%)since 06/26/18
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Bagsvaerd, Denmark, 20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct(R) for the treatment of adolescents (greater-than or equal...
The University Hospital Foundation (UHF), Government of Alberta, and Novo Nordisk Canada Inc. are proud to announce the winners of the 2019 Novo Nordisk Alberta Diabetes (NOVAD) Fund Competition. NOVAD...
BMY vs. NVO: Which Stock Is the Better Value Option?
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Novo Nordisk today announced that new data from its diabetes portfolio will be presented at the upcoming 79th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California...
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Preliminary revenue growth in Q1 2019 is 6.5% in constant currencies (7.4% in reported currencies) compared to the same period last year. This is in line with expectations, and guidance for revenue growth...